MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice

Scandinavian Journal of Immunology

Volumn 45, Issue 4, 1997, Pages 463-470

  Engel, A M ^a   Svane, I M ^a   Rygaard, J ^b   Werdelin, O ^a,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Kommunehospitalet ^*  (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; CANCER TRANSPLANTATION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; FEMALE; IMMUNOCOMPETENCE; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; T LYMPHOCYTE;

EID: 0031004968     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-419.x     Document Type: Article

References (35)

1. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527-30.
2. Schuler W, Weiler IJ, Schuler A et al. Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency. Cell 1986;46:963-72.
3. Bosma GC. Fried M, Custer RP, Caroll A, Gibson DM, Bosma MJ. Evidence of functional lymphocytes in some (leaky) SCID mice. J Exp Med 1988;167:1016-33.
4. Xie X, Brünner N, Jensen G, Albrectsen J, Gotthardsen B, Rygaard J. Comparative studies between nude and SCID mice on the growth and metastatic behavior of xenografted human tumors. Clin Exp Metastasis 1992;10:201-10.
5. Billström A. Differential expression of uPA in aggressive (DU 145) and nonaggressive (1013L) human prostate cancer xenograft. Prostate 1995;26:94-104.
6. Garofalo A, Chirivi RGS, Scanziani E, Mayo JG, Vecchi A, Giavazzi R. Comparative study on the metastatic behavior of human tumors in nude, beige/nude/Xid and severe combined immunedeficient mice. Invasion Metastasis 1993;13:82-91.
7. Giavazzi R. 7th International Workshop on Immunodeficient Animals. 1991:A-17.
8. Sawyers CL, Gishizky ML, Quan S, Golde DW, Witte ON. Propagation of human blastic myeloid leukemias in the SCID mouse. Blood 1992;79:2089-98.
9. Cesano A, Hoxie JA, Lange B, Nowell PC, Bishop J, Santoli D. The severe combined immunedeficient (SCID) mouse as a model for human myeloid leukemias. Oncogene 1992;7:827-36.
10. Suzuki H, Yasukawa K, Saito T et al. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 1992;22:1989-93.
11. Mueller BM, Reisfeld RA. Potential of the scid mouse as a host for human tumors. Cancer Metastasis Reviews 1991;10:193-200.
12. Fidler IJ. New developments in in vivo models of neoplasia. Cancer Metastasis Reviews 1991;10:191-2.
13. Williams SS, Alosco TR, Croy BA, Bankert RB. The study of human neoplastic disease in severe combined immunodeficient mice. Lab Animal Sci 1993;43:139-46.
14. Abedi MR, Hammarström L, Hassan MS, Smith E. The SCID mouse as a model for autoimmunity. J Autoimmun 1993;6:667-74.
15. Krams SH, Dorshkind K, Gershwin ME. Generation of biliary lesions after transfer of human lymphocytes into severe combined immunodeficient (SCID) mice. J Exp Med 1989;170: 1919-30.
16. Klein G. Immune and non-immune control of neoplastic development: contrasting effects of host and tumour evolution. Cancer 1980; 45:2486-524.
17. Burnet FM. The concept of immunological surveillance. Progr Expr Tumor Res 1970;13:1-27.
18. Svane IM, Engel A, Nielsen M, Ljunggren H, Rygaard J, Werdelin O. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol 1996;26:1844-50.
19. Zinkernagel RM. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature 1974;251:547-8.
20. Yagüe J, White J, Coleclough C, Kappler J, Palmer E. Marrack P. The T-cell receptor: the alpha and beta chains define idiotype, and antigen and MHC specificity. Cell 1985;42:81-7.
21. Browning M, Bodmer WF. MHC antigens and cancer: implications for T-cell surveillance. Curr Opin Immunol 1992;4: 613-18.
22. Engel A, Svane IM, Mouritsen S, Rygaard J, Clausen J, Werdelin O. Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. APMIS 1996;104:629-39.
23. Bartlett GL. Effect of host immunity on the antigenic strength of primary tumors. J Natl Cancer Inst 1972;49:493-504.
24. Lee DR, Rubacki RJ, Lie WR, Hansen TH. The murine MHC class I genes, H-2Dq and H-2Lq are strikingly homologous to each other, H-2Ld, and two genes reported to encode tumour-specific antigens. J Exp Med 1988; 168:1719-39.
25. Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Research 1953;14:835-7.
26. Prehn LM, Lawler EM. Rank order of sarcoma susceptibility among mouse strains reverses with low concentrations of antigen. Science 1979;204:309-10.
27. Prehn RT. Relationship of tumor immunogenicity to concentration of the antigen. J Natl Cancer Inst 1975;55:189-90.
28. Outzen HC, Custer RP, Eaton GJ, Prehn RT. Spontaneous and induced tumor incidence in germfree 'nude' mice. Journal of the Reticuloendothelial Society 1975;17:1-9.
29. Johnson S. The effect of thymectomy and of the dose of 3-methylcholanthrene on the induction and antigenic properties of sarcomas in C57B1 mice. Br J Cancer 1968;22:93-104.
30. Kirchgessner CU, Patil CK, Evans JW et al. DNA-dependent kinase (p. 350) as a candidate gene for the murine SCID defect. Science 1995;267:1178-83.
31. Alt FW, Rathbun G, Oltz E, Taccioli G, Shinkai Y. Function and control of recombination-activating gene activity. Annals NY Acad Sci 1992;651:277-94.
32. Pantelouris EM. Absence of thymus in a mouse mutant. Nature 1968;217:370.
33. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphoytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974;248:701-2.
34. Braciale TJ. Antigen processing for presentation by MHC class I molecules. Curr Opin Immunol 1992;4:59.
35. Neefjes JJ, Momburg F. Cell biology of antigen presentation. Curr Opin Immunol 1993;5:27-34.